GSE197555 trametinib A-549 NCI-H460 0 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE197555_trametinib_A-549 NCI-H460_0_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE197555_trametinib_A-549 NCI-H460_0_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE197555_trametinib_A-549 NCI-H460_0_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE197555_trametinib_A-549 NCI-H460_0_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 3

Gene

colony stimulating factor 2 receptor subunit alpha

Gene

uncharaterized LOC112694756

Gene

small nucleolar RNA host gene 4

Gene

RNA polymerase II subunit J3

Gene

CDH13 antisense RNA 2

Gene

ribosomal protein S2 pseudogene 5

Gene

SLC12A2 divergent transcript

Gene

FEZF1 antisense RNA 1

Gene

MIR193b-365a host gene

  • Gene

    small nucleolar RNA host gene 3


  • Gene

    colony stimulating factor 2 receptor subunit alpha


  • Gene

    uncharaterized LOC112694756


  • Gene

    small nucleolar RNA host gene 4


  • Gene

    RNA polymerase II subunit J3


  • Gene

    CDH13 antisense RNA 2


  • Gene

    ribosomal protein S2 pseudogene 5


  • Gene

    SLC12A2 divergent transcript


  • Gene

    FEZF1 antisense RNA 1


  • Gene

    MIR193b-365a host gene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.